Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel small-molecule oral therapeutics that use targeted protein degradation (TPD). Its Pegasus platform is designed to degrade disease-causing proteins that are hard to drug with traditional inhibitors. The company's focus is immunology-inflammation diseases. Its pipeline includes the IRAK4 degrader KT-474 (SAR444656), partnered with Sanofi, and the STAT6 degrader KT-621.